Literature DB >> 25518844

Stimulant use disorders in people with psychosis: a meta-analysis of rate and factors affecting variation.

Grant E Sara1, Matthew M Large2, Sandra L Matheson3, Philip M Burgess4, Gin S Malhi5, Harvey A Whiteford6, Wayne D Hall7.   

Abstract

OBJECTIVE: Stimulant abuse and dependence often complicate the care of people with psychotic disorders. This study systematically reviews the prevalence estimates reported for stimulant abuse and dependence in people with psychotic disorders, and examines personal, clinical, regional and methodological factors which explain variation in these rates.
METHODS: PsychINFO, EMBASE and MEDLINE (1946-2013) were searched systematically for studies reporting on stimulant drug use disorders in representative samples of people with psychotic disorders. Random effects models estimated the pooled rate of a stimulant use disorder, defined to include stimulant abuse and stimulant dependence. Study characteristics associated with heterogeneity in rates of stimulant use disorder were examined by subgroup analyses for categorical variables, by meta-regression for continuous independent variables and by multiple meta-regression.
RESULTS: Sixty-four studies provided 68 estimates of lifetime or recent stimulant use disorders in 22,500 people with psychosis. The pooled rate of stimulant use disorder was 8.9% (95% CI 7.4%, 10.5%). Higher rates of stimulant use disorders were reported in studies of affective psychosis, studies from inpatient settings, studies from the USA and Australia, and studies with higher rates of cannabis disorder; in multiple meta-regression analysis these factors explained 68% of between-study variance. Rates of stimulant use disorder were stable over time, and unrelated to age, sex, stage of psychosis, type of stimulant drug or study methodology factors.
CONCLUSIONS: Reported rates of stimulant use disorder in people with psychosis are much higher than in the general population but vary widely and are associated with regional, service setting and clinical differences between studies. It is likely that stimulants contribute to the overall burden of psychosis, and that social and environmental factors combine with drug and illness-related factors to influence stimulant use in psychosis. © The Royal Australian and New Zealand College of Psychiatrists 2014.

Entities:  

Keywords:  affective psychosis; amphetamine; cocaine; ecstasy; schizophrenia; systematic review

Mesh:

Substances:

Year:  2014        PMID: 25518844     DOI: 10.1177/0004867414561526

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  11 in total

1.  Altered gut microbiota associated with symptom severity in schizophrenia.

Authors:  Shijia Li; Min Zhuo; Xia Huang; Yuanyuan Huang; Jing Zhou; Dongsheng Xiong; Jiahui Li; Ya Liu; Zhilin Pan; Hehua Li; Jun Chen; Xiaobo Li; Zhiming Xiang; Fengchun Wu; Kai Wu
Journal:  PeerJ       Date:  2020-07-29       Impact factor: 2.984

2.  The prevalence and clinical correlates of substance use disorders in patients with psychotic disorders from an Upper-Middle-Income Country.

Authors:  Henk S Temmingh; Sumaya Mall; Fleur M Howells; Goodman Sibeko; Dan J Stein
Journal:  S Afr J Psychiatr       Date:  2020-07-28       Impact factor: 1.550

Review 3.  Engagement with online psychosocial interventions for psychosis: A review and synthesis of relevant factors.

Authors:  Chelsea Arnold; John Farhall; Kristi-Ann Villagonzalo; Kriti Sharma; Neil Thomas
Journal:  Internet Interv       Date:  2021-06-05

4.  Perinatal Treatments with the Dopamine D₂-Receptor Agonist Quinpirole Produces Permanent D₂-Receptor Supersensitization: a Model of Schizophrenia.

Authors:  Richard M Kostrzewa; Przemysław Nowak; Ryszard Brus; Russell W Brown
Journal:  Neurochem Res       Date:  2015-11-07       Impact factor: 3.996

Review 5.  Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth.

Authors:  Sabina Abidi; Irfan Mian; Iliana Garcia-Ortega; Tania Lecomte; Thomas Raedler; Kevin Jackson; Kim Jackson; Tamara Pringsheim; Donald Addington
Journal:  Can J Psychiatry       Date:  2017-08-02       Impact factor: 4.356

6.  First-episode psychosis and substance use in Nelson Mandela Bay: Findings from an acute mental health unit.

Authors:  Yanga Thungana; Zukiswa Zingela; Stephan van Wyk
Journal:  S Afr J Psychiatr       Date:  2019-10-24       Impact factor: 1.550

7.  Predictors of controlled prescription drug non-medical and lifetime use among patients accessing public mental health services in Uganda: a cross-sectional study.

Authors:  Pakoyo Fadhiru Kamba; John Mulangwa; Peter Kageni; Sulah Balikuna; Allan Kengo; Brian Byamah Mutamba; Nelson Sewankambo; Richard Odoi Adome; Pauline Byakika-Kibwika
Journal:  BMJ Open       Date:  2021-03-26       Impact factor: 2.692

8.  Psychosocial interventions for people with both severe mental illness and substance misuse.

Authors:  Glenn E Hunt; Nandi Siegfried; Kirsten Morley; Carrie Brooke-Sumner; Michelle Cleary
Journal:  Cochrane Database Syst Rev       Date:  2019-12-12

Review 9.  Holistic Management of Schizophrenia Symptoms Using Pharmacological and Non-pharmacological Treatment.

Authors:  Pronab Ganguly; Abdrabo Soliman; Ahmed A Moustafa
Journal:  Front Public Health       Date:  2018-06-07

Review 10.  Non-Genetic Factors in Schizophrenia.

Authors:  Simona A Stilo; Robin M Murray
Journal:  Curr Psychiatry Rep       Date:  2019-09-14       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.